An Open-label, Single Ascending-dose, Pharmacokinetic and Safety Study of Regadenoson (Rapidscan®) in Paediatric Patients with Cardiovascular Conditions and Diseases
Latest Information Update: 05 Oct 2017
At a glance
- Drugs Regadenoson (Primary)
- Indications Cardiovascular disorders
- Focus Adverse reactions
- Sponsors Rapidscan Pharma Solutions
- 05 Oct 2017 New trial record